Skip to main content

Table 1 Demographic and clinical characteristics (number [percent]) of the study population by year, ANRS CO3 Aquitaine and IPEC/FIOCRUZ cohorts combined

From: AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies

  2000 2001 2002 2003 2004 2005 2006 2007 2008
Number of patients 3911 4165 4375 4568 4898 5267 5621 5916 6144
Age in yearsa          
< 30 430 (11.0) 419 (10.1) 364 (8.3) 336 (7.4) 325 (6.6) 384 (7.3) 426 (7.6) 456 (7.7) 483 (7.9)
30-39 1830 (46.8) 1808 (43.4) 1787 (40.8) 1690 (37) 1614 (33) 1563 (29.7) 1501 (26.7) 1494 (25.3) 1462 (23.8)
40-49 1127 (28.8) 1316 (31.6) 1505 (34.4) 1715 (37.5) 1987 (40.6) 2183 (41.4) 2422 (43.1) 2547 (43.1) 2603 (42.4)
50-59 359 (9.2) 435 (10.4) 518 (11.8) 597 (13.1) 700 (14.3) 811 (15.4) 905 (16.1) 982 (16.6) 1093 (17.8)
> = 60 165 (4.2) 187 (4.5) 201 (4.6) 230 (5) 272 (5.6) 326 (6.2) 367 (6.5) 437 (7.4) 503 (8.2)
Gender          
Male 2725 (69.7) 2879 (69.1) 3039 (69.5) 3175 (69.5) 3418 (69.8) 3679 (69.9) 3898 (69.3) 4096 (69.2) 4256 (69.3)
Mode of HIV transmissionb        
Heterosexual 1129 (28.9) 1274 (30.6) 1371 (31.3) 1464 (32) 1613 (32.9) 1798 (34.1) 1994 (35.5) 2176 (36.8) 2328 (37.9)
MSM 1383 (35.4) 1471 (35.3) 1575 (36) 1682 (36.8) 1817 (37.1) 1963 (37.3) 2102 (37.4) 2221 (37.5) 2320 (37.8)
IDU 1011 (25.9) 996 (23.9) 984 (22.5) 955 (20.9) 965 (19.7) 947 (18) 933 (16.6) 909 (15.4) 858 (14)
Other 145 (3.7) 150 (3.6) 151 (3.5) 155 (3.4) 155 (3.2) 157 (3) 165 (2.9) 161 (2.7) 166 (2.7)
Unknown 243 (6.2) 274 (6.6) 294 (6.7) 312 (6.8) 348 (7.1) 402 (7.6) 427 (7.6) 449 (7.6) 472 (7.7)
CD4 cell countc         
> 500 1306 (38.3) 1412 (39.5) 1580 (41) 1646 (41.9) 1768 (40.7) 1996 (41.9) 2274 (44.9) 2457 (45.3) 2720 (47.2)
351-500 787 (23.1) 866 (24.2) 920 (23.9) 924 (23.5) 1075 (24.7) 1167 (24.5) 1225 (24.2) 1375 (25.4) 1453 (25.2)
201-350 777 (22.8) 783 (21.9) 795 (20.6) 852 (21.7) 931 (21.4) 963 (20.2) 997 (19.7) 985 (18.2) 1017 (17.7)
51-200 427 (12.5) 410 (11.5) 449 (11.7) 414 (10.5) 446 (10.3) 502 (10.5) 459 (9.1) 501 (9.2) 479 (8.3)
<= 50 114 (3.3) 107 (3) 107 (2.8) 94 (2.4) 128 (2.9) 132 (2.8) 115 (2.3) 103 (1.9) 93 (1.6)
Plasma HIV RNAc         
<= 400 1151 (33.8) 1324 (37.3) 1628 (42.3) 1859 (47.3) 2100 (48.8) 2514 (53.5) 2908 (58.5) 3348 (63.1) 3898 (68.4)
401-3000 749 (22) 795 (22.4) 689 (17.9) 598 (15.2) 613 (14.3) 604 (12.8) 557 (11.2) 511 (9.6) 518 (9.1)
3001-10000 475 (13.9) 451 (12.7) 445 (11.6) 409 (10.4) 393 (9.1) 396 (8.4) 345 (6.9) 354 (6.7) 318 (5.6)
10001-100000 725 (21.3) 716 (20.2) 781 (20.3) 789 (20.1) 871 (20.3) 862 (18.3) 787 (15.8) 805 (15.2) 721 (12.6)
> 100000 308 (9) 267 (7.5) 306 (8) 277 (7) 323 (7.5) 325 (6.9) 378 (7.6) 288 (5.4) 246 (4.3)
≤ 1 year since first HIV + testd       
Yes 439 (11.2) 350 (8.4) 337 (7.7) 316 (6.9) 316 (6.5) 421 (8.0) 493 (8.8) 496 (8.4) 501 (8.2)
On cARTe         
Yes 3506 (89.6) 3724 (89.4) 3932 (89.9) 4101 (89.8) 4393 (89.7) 4684 (88.9) 4913 (87.4) 5197 (87.8) 5508 (89.6)
Hepatitis Bf          
Yes 215 (6.1) 235 (6.2) 249 (6.2) 258 (6.1) 280 (6.2) 305 (6.3) 331 (6.4) 348 (6.4) 367 (6.6)
Hepatitis Cg          
Yes 949 (26.7) 968 (25.5) 1013 (25.2) 1022 (24.2) 1027 (22.6) 1008 (20.5) 1018 (19.4) 999 (18.2) 978 (17.3)
  1. aAge from birth was updated yearly for each participant.
  2. bPresumed mode of HIV exposure was classified as men who have sex with men (MSM), injection drug use (IDU), heterosexual transmission, other, and unknown.
  3. cYearly CD4 cell counts and plasma HIV RNAs were defined as the mean value of all measurements taken in a specific calendar year.
  4. dTime since first HIV + test was calculated for each calendar year.
  5. eCombination antiretroviral therapy (cART) was defined as two nucleoside reverse transcriptase inhibitors plus either one non-nucleoside reverse transcriptase inhibitor or one protease-inhibitor (boosted or not).
  6. fHepatitis B infection was defined by the presence of hepatitis B surface antigen (HBsAg).
  7. gHepatitis C infection was defined by the presence of hepatitis C antibodies.